Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Revenue (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Revenue for 5 consecutive years, with $21.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue changed N/A year-over-year to $21.2 million, compared with a TTM value of $51.1 million through Sep 2025, up 406.13%, and an annual FY2024 reading of $10.1 million, up 496.0% over the prior year.
  • Revenue was $21.2 million for Q3 2025 at Autolus Therapeutics, up from $20.9 million in the prior quarter.
  • Across five years, Revenue topped out at $21.2 million in Q3 2025 and bottomed at -$1.8 million in Q1 2022.
  • Average Revenue over 4 years is $7.6 million, with a median of $5.1 million recorded in 2023.
  • The sharpest move saw Revenue surged 681.73% in 2024, then dropped 11.07% in 2025.
  • Year by year, Revenue stood at -$1.8 million in 2022, then skyrocketed by 122.68% to $406000.0 in 2023, then plummeted by 95.07% to $20000.0 in 2024, then surged by 105870.0% to $21.2 million in 2025.
  • Business Quant data shows Revenue for AUTL at $21.2 million in Q3 2025, $20.9 million in Q2 2025, and $9.0 million in Q1 2025.